Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—doxycycline, metronidazole, and cefdinir. Each component has a distinct mechanism of action and antimicrobial spectrum: - Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is active against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms[3]. - Metronidazole is a nitroimidazole antibiotic that disrupts DNA synthesis in anaerobic bacteria and certain protozoa by generating free radicals after reduction within the microbial cell[2][6]. - Cefdinir is an oral third-generation cephalosporin (beta-lactam) antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. It covers many gram-positive and some gram-negative organisms[7][10]. This combination would provide broad-spectrum coverage against aerobic, anaerobic, gram-positive, and gram-negative pathogens. Such combinations are not standard but may be considered in complex or mixed infections where multiple types of bacteria are suspected or confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxycycline + metronidazole + cefdinir.